Disc Medicine, Inc. (IRON) stock
Close on Nov 16, 2026Market cap $2.94BP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $2.94B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 4.56
- Dividend yield
- –
- Free cash flow yield
- -6.72%
Fundamentals
- Net income
- -$245.89M
- EPS, diluted
- -$6.57
- Free cash flow
- -$197.58M
- Book value per share
- $16.65
- Diluted shares
- 39M
Trading
- Next earnings
- Feb 25, 2027 (estimated, before the open)
- Previous close
- $80.00
- Open
- $80.12
- Day's range
- $76.40 – $80.37
- Volume
- 817,338
- Average volume (20 days)
- 1,328,784
- Index membership
- Russell 2000 (since Jun 2023), Russell 3000 (since Aug 2023)
- 52-week range
- $40.00 – $99.50
- RSI (14 days)
- 49.1
- Volatility (1 year)
- 63.6%
- Relative volume
- 1.08×
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 16, 2026. The S&P 500 is measured by the SPY fund.
| Period | IRON | S&P 500 | Difference | IRON per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +34.7% | -3.1% | +37.8 pts | ||
| 3 months | -2.9% | -4.5% | +1.6 pts | ||
| Year to date | -3.6% | +9.4% | −12.9 pts | ||
| 1 year | -14.9% | +11.3% | −26.2 pts | ||
| 3 years | +58.4% | +70.4% | −12.0 pts | +16.6% | +19.4% |
| 5 years | +95.4% | +68.6% | +26.8 pts | +14.3% | +11.0% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Disc Medicine filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Disc Medicine Announces Success on All Primary and Secondary Endpoints in the Pivotal Phase 3 APOLLOUpdate
- Update
- Update
About Disc Medicine
Pharmaceutical Preparations
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic treatments for patients suffering from serious hematologic conditions. The company focuses on biological mechanisms regulating red blood cell production and function, specifically targeting heme biosynthesis and iron homeostasis. Its development pipeline includes bitopertin for erythropoietic porphyrias such as erythropoietic protoporphyria and X-linked protoporphyria, DISC-0974 for anemia related to myelofibrosis and inflammatory bowel disease, and DISC-3405 for polycythemia vera and sickle cell disease. Additionally, the company is advancing a preclinical candidate, DISC-0998, for inflammatory anemia. Its target patient population consists of individuals with these blood disorders.
Company profile, executives and historyDisc Medicine stock: common questions
What is Disc Medicine's stock price?
IRON closed at $76.59 on Nov 16, 2026, down 4.26% on the day. Over the past 52 weeks it traded between $40.00 and $99.50.
What is Disc Medicine's market cap?
Disc Medicine was worth $2.94B at the close on Nov 16, 2026: the share price times the diluted shares outstanding.
What is IRON's P/E ratio?
Disc Medicine lost money over the twelve months to Jun 30, 2026 (diluted EPS -$6.57), so it has no meaningful P/E ratio.
Does Disc Medicine pay a dividend?
No. Disc Medicine has not paid a cash dividend over the last twelve months.
When does Disc Medicine report earnings next?
Disc Medicine is expected to report Q4 FY2026 results on Feb 25, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has IRON stock performed over the past year?
Including dividends, IRON returned -14.9% over the past year, against +11.3% for the S&P 500.
How many IRON shares are sold short?
7M shares were sold short at the latest FINRA report, 25.34% of the float, or 3.2 days of average trading volume.
Who are Disc Medicine's competitors?
Companies most similar to Disc Medicine by business, industry and size include DMRA, FULC, DMAC, KROS, AGIO.
See a number that looks wrong?